Jonathan Michael Licht, M.D.

San Diego, CA

Education

EMG & Neuromuscular Fellowship
Henry Ford Hospital, Detroit, NH 1985-1986

Neurology Residency
Henry Ford Hospital 1983-1985
University of Califomia Irvine 1980-1981

Internship

Henry Ford Hospital 1979-1980

Medical School

Wayne State University, Detroit 1975-1979

Undergraduate
University of Michigan, Ann Arbor 1971-1975

Appointments

• Mercy Hospital - Chairman, Division of Neurology
• C.N.S. Medical Group: Director Clinical Research & Study
• Neurologic Disability Consultant, Department of Social Services, San Diego and Los Angeles Counties
• Qualified Medical Evaluator, State of California, Industrial Medical Council
• Sharp Memorial and Sharp Cabrillo Hospital
• Continental Rehabilitation Hospital
• Mission Bay Hospital

 

Memberships

• San Diego Medical Society
• San Diego Neurological Society
• American Academy of Neurology
• California Medical Association

Certification

• Diplomate of American Board of Neurology and Psychiatry, November 1987
• American Board of Electrodiapostic Medicine, April, 1989.
• I.M.E, Q.M.E. State of Califomia
• Michigan and Califomia Licenses

Publications

Richard Alan Smith, Ellen Gillie and Jonathan Licht, Palliative Treatment of Motor Neuron disease. Center for Neurologic Study, San Diego, CA

Richard Alan Smith, Jonathan M. Licht, Peter E. Manley, Center for Neurologic Study San Diego, California; Beverly Girten and Ron Tuttle, Houghten Pharmaceuticals, Inc. San Diego, California, Testing the limits of palliative care

Licht, J., Smith, R.A., Neuromuscular Disease. Current Practice in Medicine, Roger C. Bone, M.D. (Ed.), Current Medicine, Philadelphia, (1998) Chapter 15, PP 1-9.

Smith R.A., Licht J.M., Manley P.E., Girten B., Tuttle R., (1994), Testing the limits of palliative care. "ALS-From Charot to the Present and into the Future", San Francisco, September 11 &12 1993. F.C. Rose (Ed), Smith-Gordon & Company Ltd., London, PP 315-32.

Smith R.A., Gillie. E., Licht J.M., (1991) Palliative Treatment of Motor Neuron Disease. Handbook of Clinical Neurology, Vol. 15 (59): Diseases of the Motor System. J.M.B.V. de Jong (eds.), Elsevier Science Publishers B.V., Amsterdam, PP 459-473.

Review of Nuclear Magnetic Response and Muscle Disease, Current Neurology, Vol. VIII, 1988.

Research

1. Clinical investigator for Tissue Plasminogen activator in acute strokes in collaboration with U.C.S.D. and N.I.H.
2. Clinical investigator for Dextrorphan in acute stroke in collaboration with U.C.S.D. and Hoffmann-La Roche.
3. Principal investigator in multicenter evaluation of the safety of I.V. Valproate with Abbott Labs.
4. Principal investigator in multicenter evaluation of the safety and efficacy of subcutaneous GR43175C (Sumatriptan) in patients with acute migmines. Sponsor: Glaxo, Inc.
5. Principal investigator Phase II-III prospective randomized, double blind placebo-controlled, dose ranging safety and efficacy study of recombinant human ciliary neurotrophic factor in patients with Amyotrophic Lateral Sclerosis. Sponsor: Regeneron
6. Co-investigator Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events. Sponsor: Sterling Windirop Pharmaceuticals
7. Principal investigator in multicenter evaluation of the safety and efficacy of inhaler of Sumatriptan in patients with acute migraines. Sponsor: Glaxo, Inc.
8. Principal Investigator in evaluation of the efficacy and safety of eliprodil in patients with acute ischemic stroke. sponsor: Lorex
9. Co-investigator in a trial of Recombinant Methionyl Brain Derived Neurotrophic Factor (r-methuBDNF) given by daily subcutaneous injection to patients with ALS- phase II study. sponsor: Amgen Inc.
10. Co-investigator in double-blind study to confirm the efficacy and safety of 311C90 in the treatment of acute migraine headache. sponsor: Burroughs Wellcome Co.
11. Principal Investigator in evaluation of the efficacy and safety of lubeluzole in patients with acute ischemic stroke. sponsor: Janssen
12. Principal Investigator in monotherapy study of topiramate in patients with partial complex seizures. sponsor: R.W. Johnson Pharmaceutical Research Institute
13. Principal Investigator in monotherapy study of gabapentin (neurontin) in patients with new on-set of partial complex seizures. sponsor: Parke-Davis Pharmaceutical Research
14. Principal Investigator in evaluation of the safety and efficacy of clomethiazole in patients with acute ischemic stroke, hemorrhagic stroke, and ischemic stroke treated with t-PA. sponsor: Astra-USA
15. Principal Investigator in evaluation of the safety and efficacy of GV150526 in patients with acute ischemic stroke. sponsor: Glaxo-Wellcome
16. Principal Investigator in evaluation of the safety and efficacy of citicoline in patients with acute ischemic stroke. sponsor: Interneuron Pharmaceuticals

Teaching

• Assistant Clinical Professor, Department of Neurosciences, University of California, San Diego
• Clinical Instructor of Neurology, Mercy Hospital, San Diego

Plays

The Center for Neurologic Study
© 2004 All rights reserved.
Comments about the site? Let us know.